TY - JOUR
T1 - Outward open conformation of a Major Facilitator Superfamily multidrug/H+ antiporter provides insights into switching mechanism
AU - Nagarathinam, Kumar
AU - Nakada-Nakura, Yoshiko
AU - Parthier, Christoph
AU - Terada, Tohru
AU - Juge, Narinobu
AU - Jaenecke, Frank
AU - Liu, Kehong
AU - Hotta, Yunhon
AU - Miyaji, Takaaki
AU - Omote, Hiroshi
AU - Iwata, So
AU - Nomura, Norimichi
AU - Stubbs, Milton T.
AU - Tanabe, Mikio
N1 - Funding Information:
We would like to thank Vincent Oleric and Takashi Tomizaki of the Swiss Light Source (SLS, Villingen) for assistance in data collection and Toshiya Senda for helpful discussions and support. This work was supported by the Bundesministerium für Bildung und Forschung (BMBF) program ZIK HALOmem (FKZ 03Z2HN21 to M.T.), by the European Regional Development Fund ERDF (1241090001 to M.T.S.), and in part by the Platform Project for Supporting in Drug Discovery and Life Science Research (Platform for Drug Discovery, Informatics and Structural Life Science (PDIS) and Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from the Japan Agency for Medical Research and Development (AMED) under Grant number JP18am0101107 (to T.T.), JP18am0101079 (to S.I. and N.N), and JP18am0101071 (to M. T), the ERATO Human Receptor Crystallography Project of the Japan Science and Technology Agency (JST) (to S.I.), by the Strategic Basic Research Program, JST (to S.I. and N.N), by the Targeted Proteins Research Program of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (to S.I.), and by Grants-in-Aids for Scientific Research from the MEXT (No. 22570114 to N.N.). Crystallographic data were collected at the SLS with support from the European Community’s 7th Framework Programme (FP7/2007–2013) under BioStruct-X (grant agreement No. 283570, project ID: BioStructx_5450 to M.T.).
Publisher Copyright:
© 2018, The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Multidrug resistance (MDR) poses a major challenge to medicine. A principle cause of MDR is through active efflux by MDR transporters situated in the bacterial membrane. Here we present the crystal structure of the major facilitator superfamily (MFS) drug/H+ antiporter MdfA from Escherichia coli in an outward open conformation. Comparison with the inward facing (drug binding) state shows that, in addition to the expected change in relative orientations of the N- and C-terminal lobes of the antiporter, the conformation of TM5 is kinked and twisted. In vitro reconstitution experiments demonstrate the importance of selected residues for transport and molecular dynamics simulations are used to gain insights into antiporter switching. With the availability of structures of alternative conformational states, we anticipate that MdfA will serve as a model system for understanding drug efflux in MFS MDR antiporters.
AB - Multidrug resistance (MDR) poses a major challenge to medicine. A principle cause of MDR is through active efflux by MDR transporters situated in the bacterial membrane. Here we present the crystal structure of the major facilitator superfamily (MFS) drug/H+ antiporter MdfA from Escherichia coli in an outward open conformation. Comparison with the inward facing (drug binding) state shows that, in addition to the expected change in relative orientations of the N- and C-terminal lobes of the antiporter, the conformation of TM5 is kinked and twisted. In vitro reconstitution experiments demonstrate the importance of selected residues for transport and molecular dynamics simulations are used to gain insights into antiporter switching. With the availability of structures of alternative conformational states, we anticipate that MdfA will serve as a model system for understanding drug efflux in MFS MDR antiporters.
UR - http://www.scopus.com/inward/record.url?scp=85054082708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054082708&partnerID=8YFLogxK
U2 - 10.1038/s41467-018-06306-x
DO - 10.1038/s41467-018-06306-x
M3 - Article
C2 - 30275448
AN - SCOPUS:85054082708
SN - 2041-1723
VL - 9
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 4005
ER -